Literature DB >> 3209056

Significant association of acute lymphoblastic leukemia with HLA-Cw7.

C A Müller1, R Hasmann, H Grosse-Wilde, U Vögeler, C Bei-Jun, R Dopfer, H D Waller.   

Abstract

Frequencies of all defined HLA-A, -B, -C (-DR) antigens were determined in 142 (59) Germans suffering from acute lymphoblastic leukemia (ALL) with differentiation of immunologically defined or age-related subgroups of the disease. A highly significant rise of the HLA-C locus antigen Cw7 was found in ALL patients, particularly those over the age of 11 in comparison with local German and Caucasian controls of the Ninth Int. Histocompatibility Workshop (WS). Only slight differences of HLA-Cw7 frequencies were observed within the four immunologically defined ALL subtypes of all or age-related patient groups. HLA-A, -B, or -DR antigens, as well as HLA-ABC three-locus haplotypes were similarly distributed in patients and their local or Caucasian controls. The results indicate HLA-linked genetic factors conferring susceptibility to ALL in adults, particularly those presenting with B-, T-, and Null-ALL.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3209056     DOI: 10.1002/gepi.1370050609

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  3 in total

1.  Allele-specific peptide ligand motifs of HLA-C molecules.

Authors:  K Falk; O Rötzschke; B Grahovac; D Schendel; S Stevanović; V Gnau; G Jung; J L Strominger; H G Rammensee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

2.  Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C.

Authors:  J Zemmour; P Parham
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

Review 3.  Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence.

Authors:  Kevin Y Urayama; Pamela D Thompson; Malcolm Taylor; Elizabeth A Trachtenberg; Anand P Chokkalingam
Journal:  Front Oncol       Date:  2013-12-12       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.